Award
National Cancer Institute 5R01CA287734-02
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
Recipient
National Cancer Institute (NCI), part of the NIH, United States
Award Amount
$670,358.00
Ceiling
$670,358.00
Awarded
July 30, 2025
Identifier
5R01CA287734-02
NIH National Cancer Institute awarded $670,358 for research on B lineage cells' role in lung cancer response to immune therapy, aiming to develop new therapies for early-stage NSCLC.
Description
This project focuses on understanding the role of B lineage cells in lung cancer response to immune therapy, leveraging clinical trials, mouse models, and advanced sequencing technologies. The award is funded by the NIH's National Cancer Institute with a total budget of approximately $670,358 for the fiscal year 2025. The project aims to develop B cell-centric therapies to improve patient outcomes in early-stage non-small cell lung cancer (NSCLC).